Afib Clinical Trials 2023

Afib Clinical Trials 2023

Afib research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in afib clinical trials today.

Afib Clinical Trials

Here are the 6 most popular medical studies for afib

Popular filter options for afib trials

Stroke Clinical Trials

View 14 Stroke medical studies.

Hemorrhagic Stroke Clinical Trials

View 12 Hemorrhagic Stroke medical studies.

Phase 3 Afib Clinical Trials

View 99 phase 3 afib medical studies.

Afib Clinical Trials With No Placebo

View 99 afib medical studies that do not have a placebo group.

View More Afib Trials

See another 77 medical studies focused on afib.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to afib

What are the top hospitals conducting afib research?

When it comes to the ongoing battle against atrial fibrillation (afib), several top hospitals are leading the way in clinical trials. One such institution is Massachusetts General Hospital, located in Boston. With nine active afib trials and a remarkable 61 completed trials throughout their history, they have been at the forefront of tackling this cardiac condition since recording their first trial in 2003. Moving north to Canada, the University of Ottawa Heart Institute has emerged as another key player in afib research. This renowned institute boasts nine ongoing trials along with 29 previously conducted studies since initiating their inaugural trial back in 2000.

Meanwhile, at Montreal Heart Institute, also situated within Canada's vibrant medical landscape, researchers are actively engaged in six clinical trials focused on afib while having accomplished an impressive tally of 26 previous investigations dating back to their initial trial in 2000. In Birmingham's Grandview Medical Center, innovative efforts continue with six active afib trials building upon a foundation laid down by nineteen earlier endeavors that commenced only eight years ago with their initiation into conducting ground-breaking inquiries surrounding atrial fibrillation.

Lastly yet significantly worth mentioning is Cleveland Clinic located within Ohio which presently embarks five distinct atrial fibrillation studies contributing towards pathbreaking advancements whilst carrying out twenty-eight prior investigations; theirs can be traced all way through two decades starting from ancient1999.

These esteemed hospitals represent pillars of hope for those grappling with atrial fibrillation and showcase how medical professionals across borders are unitedly working towards unraveling mysteries around this condition. By being involved not just within respective local communities but also global scientific community these institutions bring together diverse expertise paving paths ahead improving lives worldwide

Which are the best cities for afib clinical trials?

In the realm of afib clinical trials, several cities emerge as leaders in research and development. New york, New York tops the list with 28 active trials investigating treatments like Pulse Field Ablation and WATCHMAN FLX Implant. Montreal, Quebec follows closely behind with 23 ongoing studies focusing on interventions such as Catheter ablation and Apixaban. Meanwhile, Boston, Massachusetts boasts 21 active trials exploring options like Antiplatelet Therapy and Left Atrial Appendage Occlusion. Lastly, Toronto, Ontario and Ottawa, Ontario contribute to this vital research field with their respective 20 and 18 active trials examining a range of potential therapies for afib patients. These cities serve as beacons of hope for individuals seeking innovative approaches to manage atrial fibrillation effectively

Which are the top treatments for afib being explored in clinical trials?

Exciting advancements are being made in the realm of afib treatments, with several notable contenders taking center stage in ongoing clinical trials. Intervention leads the pack with four active trials and an impressive track record of two all-time afib trials since its initial listing in 2012. Following closely behind is apixaban, showing promise with two active trials and a substantial history of 47 all-time afib trials dating back to 2007. Catheter ablation also holds its own, participating in two current studies and boasting a considerable presence with 28 all-time afib trials since its introduction in 2009. Amiodarone proves itself as another worthy contender, engaging in two active clinical trials while accumulating an impressive tally of 34 all-time afib trials starting from1998. Additionally, a novel approach through a twelve-week supervised exercise-based cardiac rehabilitation program has shown potential demonstrated by one ongoing trial introduced this year—holding great promise for future treatment options.

What are the most recent clinical trials for afib?

Exciting advancements are being made in the field of atrial fibrillation (afib) treatment, as evidenced by recent clinical trials. One such trial investigates the potential benefits of stellate ganglion block for afib patients, with both Phase 2 and Phase 3 studies currently underway. Another study explores an as-needed rate control approach for managing afib symptoms, showing promise in its Phase 1 stage. Additionally, a Phase 3 trial focuses on evaluating the effectiveness of Asundexian in treating afib. The Colchicine arm study is also at its final phase, aiming to determine if this medication can provide significant relief for individuals with afib. Lastly, a large-scale Phase 4 trial assesses the efficacy and safety profile of oral anticoagulants specifically designed for those living with atrial fibrillation. These ongoing trials offer hope for improved management strategies and enhanced quality of life among afib patients.

What afib clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of atrial fibrillation (afib) research. In May 2021, St. Vincent Cardiovascular Research Institute successfully completed a trial investigating the effectiveness of Colchicine for this common heart rhythm disorder. Wake Forest University Health Sciences also concluded a trial examining Methohexital in April 2020. Additionally, Allergan's AGN-151607 study reached completion in March 2019, and Population Health Research Institute wrapped up their investigation into Colchicine for afib treatment in February 2018. These studies represent important contributions towards advancing our understanding and management of atrial fibrillation.